ten Hoorn, Sanne
Waasdorp, Cynthia
van Oijen, Martijn G. H.
Damhofer, Helene
Trinh, Anne
Zhao, Lan
Smits, Lisanne J. H.
Bootsma, Sanne
van Pelt, Gabi W.
Mesker, Wilma E.
Mol, Linda
Goey, Kaitlyn K. H.
Koopman, Miriam
Medema, Jan Paul
Tuynman, Jurriaan B.
Zlobec, Inti
Punt, Cornelis J. A.
Vermeulen, Louis
Bijlsma, Maarten F.
Article History
Received: 22 June 2021
Accepted: 21 March 2022
First Online: 12 April 2022
Declarations
:
: The CAIRO2 trial obtained written informed consent from all patients to participate in the study and was performed in accordance with the Declaration of Helsinki. For the rectal cancer pilot cohort, samples were collected according to Dutch research guidelines of the Federation of Dutch Medical Scientific Societies (FDMSS), as described in “Human Tissue and Medical Research: Code of Conduct for Responsible use” and was approved by the Medical Ethical Committee board of the Amsterdam UMC (Number 2017.302/U2020.049 on 23-09-2020). When required, patients provided informed consent for sampling additional tumor tissue for study purposes.
: Not applicable.
: MFB has received research funding from Celgene and LEAD pharma, and has acted as a consultant to Servier. LV received speaker and consultancy fees from Genentech, Bayer, Servier, Boehringer-Ingelheim, MSD and Pierre Fabre. LV received unrestricted grants from Novartis, Servier, Roche and Roche Diagnostics. LV declares ongoing collaborations with Firalis, LeadPharma and Genentech. CP reports an advisory role for Nordic Pharma. AT is a scientific advisor for GenieUs Genomics. MK reports having an advisory role for Nordic Farma, Merck-Serono, Pierre Fabre, Servier, and institutional scientific grants from Bayer, Bristol Myers Squibb, Merck, Roche, Servier. No disclosures were reported by the other authors. None of the funders had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.